Immunome, Inc.
IMNM
Updated: 22/09/2026, 20:00:06
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
No summaries found.
- Share price
- $25.45
- Market cap
- $2.43B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Clay Siegall
- Employees
- 247
- IPO date
- 02/10/2020
- Beta
- 2.133
- Last dividend
- $0.00
- Day range
- $25.07 – $25.81
- 52-week range
- $9.85 – $30.06
- 1-day performance
- 1.52%
- 1-year performance
- 158.48%
- Current drawdown (1Y)
- -15.34%
- CIK
- 0001472012
- CUSIP
- 45257U108
- ISIN
- US45257U1088
- Created
- 07/12/2025, 04:42:49
- Last update
- 22/09/2026, 20:00:06
Track Immunome, Inc. with an AI analyst
See which prediction-market events move IMNM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 16:52:10
Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis
Seeking Alpha • STOCK • 09/06/2026, 06:44:27
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
The Motley Fool • STOCK • 04/04/2026, 21:05:46
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire • STOCK • 02/04/2026, 18:00:00
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
Zacks Investment Research • STOCK • 01/04/2026, 11:01:12
Immunome: Upcoming NDA, Valuation, And Investment Case
Seeking Alpha • STOCK • 11/03/2026, 01:51:15
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
The Motley Fool • STOCK • 22/02/2026, 14:03:29